A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy

• Published in: Scientific reports 2020-08, Vol.10 (1), p.14257-14257, Article 14257
• Main Authors: Ho, Yoon Khei, Woo, Jun Yung, Tu, Geraldine Xue En, Deng, Lih-Wen, Too, Heng-Phon
• Format: Article
• Language: English
• Subjects: 631/1647/1511; 631/1647/2300; 692/4028/67; Adolescent; Animals; Cancer therapies; Carpal tunnel syndrome; Cell Line, Tumor; Female; Genetic Engineering - methods; Genetic Therapy - methods; Genetic Vectors; Glioblastoma - therapy; Humanities and Social Sciences; Humans; Median nerve; Mesenchymal Stem Cell Transplantation; Mesenchymal stem cells; Mesenchymal Stem Cells - enzymology; Mesenchymal Stem Cells - metabolism; Mice; Mice, Nude; multidisciplinary; Neoplasms - therapy; Pain; Patients; Peripheral neuropathy; Platelets; Polyethyleneimine; Prodrugs - metabolism; Science; Science (multidisciplinary); Transfection - methods; Ultrasound; Young Adult
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-71224-2

Mesenchymal stem cells (MSCs) driven gene-directed enzyme prodrug therapy has emerged as a potential strategy for cancer treatment. The tumour-nesting properties of MSCs enable these vehicles to target tumours and metastases with effective therapies. A crucial step in engineering MSCs is the delivery of genetic material with low toxicity and high efficiency. Due to the low efficiency of current transfection methods, viral vectors are used widely to modify MSCs in preclinical and clinical studies. We show, for the first time, the high transfection efficiency (> 80%) of human adipose tissue derived-MSCs (AT-MSCs) using a cost-effective and off-the-shelf Polyethylenimine, in the presence of histone deacetylase 6 inhibitor and fusogenic lipids. Notably, the phenotypes of MSCs remained unchanged post-modification. AT-MSCs engineered with a fused transgene, yeast cytosine deaminase::uracil phosphoribosyltransferase (CDy::UPRT) displayed potent cytotoxic effects against breast, glioma, gastric cancer cells in vitro. The efficiency of eliminating gastric cell lines were effective even when using 7-day post-transfected AT-MSCs, indicative of the sustained expression and function of the therapeutic gene. In addition, significant inhibition of temozolomide resistant glioma tumour growth in vivo was observed with a single dose of therapeutic MSC. This study demonstrated an efficient non-viral modification process for MSC-based prodrug therapy.